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SHORT COMMUNICATION
A phase II study of carboplatin in adenocarcinoma of the oesophagus
A. Steel', M.H. Cullen2, P.W. Robertson' & H.R. Matthews'
'East Birmingham Hospital and 2Queen Elizabeth Hospital, Birmingham, UK.
Oesophageal carcinoma has a reputation for being a chemo-
resistant disease. However four phase II studies of cisplatin
have shown a response rate of 22% in 73 patients when used
as a single agent (Kelsen, 1984a). The toxicity of cisplatin
may be severe with nausea, vomiting, neurological and renal
damage. Carboplatin is a cisplatin analogue which is less
nephrotoxic and less neurotoxic than the parent compound
and can be given to out-patients. It has some activity in
oesophageal squamous cell carcinoma (Kelsen et al., 1984b;
Sternberg et al., 1985), but has no activity in adeno-
carcinoma of the stomach or the cardia (Kelsen et al.,
1984b). We report a phase II study of carboplatin in patients
with adenocarcinoma of the oesophagus.
Previously untreated, consenting, ambulatory (WHO per-
formance status 0, 1 or 2), patients with evaluable adeno-
carcinoma of the oesophagus were eligible for this study.
Patients who were operable and those with metastatic disease
were assessed clinically and their disease evaluated by CT
scanning, barium oesophagograms and at oesophagoscopy.
The treatment schedule consisted of 400mgm-2 i.v. carbo-
platin given over 30min in normal saline (modified in cases
of renal impairment Table I). This was repeated at 29 days
(modified by the nadir, day 22, FBC Table II). If the platelet
count was below 100 or the white cell count below 3.5 on
day 29 then the second course was delayed for one week or
until these levels were reached.
Each patient was to receive two courses of treatment and
then the response evaluated 28 days after the second course
using the criteria of Miller et al. (1981).
Fifteen male patients were entered into the study and
14 were evaluable, one patient died of a gastrointestinal
haemorrhage prior to his second CT scan. Characteristics of
the treated population are summarised in Table III. There
was no response in any oesophageal tumour with stable
disease recorded in 10 patients and progression in four. As
there was no response in the 14 evaluable patients then the
true activity in this disease is <20% with 95% confidence
(Gehan, 1961).
Ten patients were thought to be resectable but at surgery
two were found to have liver secondaries and therefore only
eight patients had a resection. Of the two patients with liver
secondaries, one was intubated and died at 2 months, the
other had a dilatation and is alive with disease at 10 months.
In the eight patients who had a resection there was one post-
operative death. Two patients died of metastatic disease at 6
and 8 months and one collapsed at home and died at 4
months. The remaining four are alive and disease free at 14,
10, 10 and 6 months.
Two patients had liver deposits at entry. Both these died
at 3 months. One patient had lung metastases and died at 13
months. One patient with severe cardiopulmonary disease
who was not fit for surgery remains alive with disease at 6
months.
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Table I Dose modification in
impairment.
relation to renal
Creatinine clearance
(mlmin-1) Percentage of dose
>60 100%
40-59 75%
30-39 50%
<30 0%
Table II Dose modification in relation to platelet and white
cell counts.
Platelets
(nadir)
> 150
100-149
75-99
50-74
25-49
<25
White cells
(nadir)
>4
>4
3-3.9
2-2.9
1-1.9
<1
Percentage of dose
120%
110%
100%
90%
75%
50%
Table III Characteristics of the carboplatin-treated population.
No. of
Characteristic patients
Entered 15
Evaluable 14
Median age 62 (range 49-72)
Male 15
Performance scale at entry WHO grade 0 13
WHO grade 1 2
Site of tumour lower oesophagus 14
middle oesophagus 1
Toxicity was mild and manageable. Nausea and vomiting
WHO grade 1 or 2 was seen after 20 of the 29 courses
assessed. Severe haematological toxicity WHO grade 3 was
only seen in two patients. Nephrotoxicity was mild with only
one patient having a WHO grade 1 elevation of his serum
creatinine.
Adenocarcinoma of the oesophagus is increasing in inci-
dence in both sexes but especially in males (Matthews et al.,
1987). Carboplatin appears to be ineffective as a single agent
at a dose of 400mgm2 in this disease. The drug is suitable
for day-case administration and the toxicity is mild and
manageable. Further studies of chemotherapy in this disease
are required to prolong the survival of patients with inoper-
able disease and in those where resection is possible.
This study was funded by the Oesophageal Cancer Research Appeal
(OCRA), Birmingham.
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